ELCC: Denosumab Improves Overall Survival in Patients with Lung Cancer

Share this content:

(ChemotherapyAdvisor) – Denosumab significantly improves overall survival when compared with zoledronic acid in patients with lung cancer and bone metastases, according to results of an exploratory analysis of a Phase 3 randomized study of the agents for preventing skeletal-related events presented at the 3rd European Lung Cancer Conference in Geneva, Switzerland, April 18–21.

Denosumab (XGEVA) is a fully human RANKL antibody approved to prevent skeletal-related events in patients with solid tumors and bone metastasis. The multinational Phase 3 study randomly assigned patients with bone metastases from solid tumors (except breast and prostate) or with multiple myeloma to either a monthly subcutaneous denosumab injection 120mg or intravenous zoledronic acid 4mg (dose adjusted for renal function). Daily calcium and vitamin D supplements were recommended.

In this analysis, overall survival was assessed among 811 patients with lung cancer enrolled in the study, 702 with non–small-cell lung cancer (NSCLC) and 109 with small cell lung cancer (SCLC), who received either denosumab or zoledronic acid. Mean age was 61 years; most patients were male (71%) and Caucasian (88%) and had an Eastern Cooperative Oncology Group performance status of 0 or 1 (85% for denosumab and 80% for zoledronic acid). The majority of patients (89%) in each treatment group had received prior chemotherapy.

Scagliotti et al. found that overall survival was prolonged with denosumab over zoledronic acid for all patients with lung cancer: median survival was 8.9 months vs. 7.7 months (HR 0.80; P=0.01), as well as for the subgroups with NSCLC (9.5 months vs. 8.1 months, HR 0.78; P=0.01) and SCLC (7.6 months vs. 5.1 months, HR 0.81; P=0.36). The difference in overall survival observed between the two groups was not affected by prior chemotherapy or difference in ECOG status, they reported.

For patients with squamous cell carcinoma (n=163), median overall survival was 8.6 months for denosumab and 6.4 months for zoledronic acid (HR 0.68; P=0.035) and, for adenocarcinoma, 9.6 months vs. 8.2 months, respectively (HR 0.80; P=0.075).

A total of 96.8% of patients reported adverse events (AEs) with denosumab and 95.4% with zoledronic acid. Serious AEs occurred in 66.0% of patients in the denosumab group and 72.9% in the zoledronic acid arm; osteonecrosis of the jaw occurred in 0.7% and 0.8% of the denosumab and zoledronic arms, respectively. Adverse event rates for hypocalcemia were 8.6% for denosumab and 3.8% for zoledronic acid.

Abstract 168O

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs